Welcome to our dedicated page for Cooper SEC filings (Ticker: COO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The CooperCompanies, Inc. (Nasdaq: COO) files a range of documents with the U.S. Securities and Exchange Commission that provide detail on its operations as a global medical device company. These SEC filings cover its two business units, CooperVision and CooperSurgical, and include information on revenue, segment performance, margins, cash flow, and significant corporate actions.
On this page, you can review annual reports on Form 10‑K and quarterly reports on Form 10‑Q, which typically present consolidated financial statements, segment data for CooperVision and CooperSurgical, discussions of non‑GAAP measures, and explanations of items such as acquisition and integration‑related charges, business optimization charges, and product line exits. These filings also describe how the company defines and uses metrics like constant currency revenue growth, organic revenue growth, and free cash flow.
Current reports on Form 8‑K provide timely updates on material events, such as quarterly earnings releases, changes in executive responsibilities, and governance developments. For example, recent 8‑K filings have addressed the reporting of quarterly financial results and the assumption of principal accounting officer responsibilities by the company’s Chief Financial Officer. Proxy statements referenced in these filings contain biographical and governance information about directors and senior executives.
Stock Titan enhances access to COO filings by offering AI‑powered summaries that explain key sections of lengthy documents in plain language. Real‑time updates from EDGAR ensure that new 10‑K, 10‑Q, and 8‑K filings appear quickly, while insider transaction reports on Form 4, when available, can be used to monitor trading activity by officers and directors. These tools help users navigate CooperCompanies’ regulatory disclosures more efficiently and understand the financial and governance details that shape the company’s performance.
CooperCompanies executive Brian G. Andrews, EVP, CFO & Treasurer, reported an amended stock option award. The filing corrects the number of shares issuable under a previously reported option grant to 41,563 shares of common stock at an exercise price of $99.08 per share.
The options were granted on 12/10/2024, are held directly, and expire on 12/10/2034. They vest at 25% per year over four years starting on the grant date, reflecting time-based equity compensation rather than an open-market stock purchase or sale.
Cooper Companies’ President & CEO, who is also a director, received a grant of stock options covering 184,069 shares of common stock on 12/10/2024. The options have an exercise price of $99.08 and expire on 12/10/2034.
The Form 4/A states it is filed solely to correct the number of shares issuable upon exercise of this previously reported option grant. The options vest at 25% per year over four years beginning on the grant date, and the full 184,069 options are reported as directly beneficially owned.
The Cooper Companies, Inc. amended its debt agreements to adjust terms on its term loan and revolving credit facilities. The company extended the maturity of
The amendment also removes the prior credit spread adjustment and raises the cap on incremental term loans to the greater of
A related amendment to the revolving credit agreement aligns its provisions with the revised term loan agreement, including the removal of credit spread adjustments.
Cooper Companies director Colleen Jay reported exercising stock options and increasing her direct shareholdings. On 01/12/2026, she exercised 7,064 stock options with an exercise price of $39.4 per share, converting them into the same number of shares of Common Stock.
Following this transaction, she directly held 36,585 shares of Common Stock. The exercised stock option award was fully used, leaving 0 derivative securities of that option grant outstanding.
Cooper Companies, Inc. director Walter M. Rosebrough Jr. filed an initial statement of beneficial ownership, reporting indirect control over 10,000 shares of common stock as of 01/03/2026. These shares are held by the Walter M Rosebrough, Jr Revocable Trust, for which he serves as sole trustee, so the position is reported as indirectly owned rather than held in his own name. The filing does not show any recent stock purchase or sale, only the existing ownership position.
Cooper Companies, Inc. (COO)01/08/2026, 18,340 restricted stock units were converted into common stock at an exercise price of $0.00 per share, increasing his directly held common stock to 254,491 shares. On the same date, he disposed of 9,419 common shares at a price of $83.13 per share, leaving 245,072 common shares directly owned after the transactions. Following these events, he also held 36,676 restricted stock units, which vest annually over four years, subject to continued service, with no stated expiration date.
Cooper Companies, Inc. executive Gerard H Warner III reported multiple equity award events on 01/08/2026. As President of CooperVision, Inc., he converted several blocks of restricted stock units into common stock at an exercise price of
On the same date, shares of common stock were withheld in several code F transactions at
Cooper Companies, Inc. president Holly R. Sheffield reported equity award activity on January 8, 2026. Several blocks of restricted stock units (RSUs) converted to common stock at an exercise price of
After these transactions, she directly held 43,261 shares of common stock and 9,462 RSUs. The RSU awards vest in four annual installments of 25% each over four years, with specific schedules described for the 1,592-share, 3,304–3,308-share, and 3,154-share grants, all subject to continued service and with no stated expiration date for the RSUs.
Cooper Companies executive Daniel G. McBride reported multiple equity transactions on 01/08/2026. Several restricted stock unit (RSU) awards were converted into common stock through transaction code M, including 4,168, 4,556, and 4,163 RSUs at an exercise price of $0.00 per share, moving into directly owned common stock. On the same date, he disposed of 2,415, 2,121, and 2,119 shares of common stock at $83.13 per share under transaction code F, leaving 69,352 shares of common stock held directly.
After these transactions, McBride also reported 12,490 RSUs beneficially owned directly. Separately, 94,496 shares of common stock are reported as held indirectly through The McBride Family Trust. Footnotes explain that the RSU awards vest 25% per year over four years, subject to continued service, and that the RSUs have no expiration date and will either vest or be forfeited.
Cooper Companies EVP, CFO & Treasurer Brian G. Andrews reported stock transactions involving restricted stock units and common stock of Cooper Companies, Inc.
On 01/08/2026, 3,528 shares of common stock were acquired at $0.00 per share upon the exercise of restricted stock units, increasing his directly held common stock to 10,430 shares. On the same date, 1,893 shares of common stock were disposed of at $83.13 per share, leaving 8,537 shares of common stock held directly.
Following these transactions, Andrews also had 22,191 shares of common stock held indirectly through the Andrews Family Trust, where he and his spouse are co-trustees, and 7,052 restricted stock units beneficially owned. The RSU award vests 25% per year over four years, with specific share amounts scheduled through 01/08/2028, and will either vest or be forfeited.
FAQ
What is the current stock price of Cooper (COO)?
What is the market cap of Cooper (COO)?
